管窥2025年处于全球研发中后期的国产创新药全景

CPHI制药在线
Nov 13

关注并星标CPHI制药在线2025年11月,一批国产创新药已迈入全球研发中后期(Ⅱ/Ⅲ期临床或注册阶段),这不仅是中国医药产业从“仿创结合”向“全球新”进阶的实证,更折射出国内药企在全球创新赛道的布局逻辑。从ADC(抗体药物偶联物)到双抗、小分子,从跨国合作到自主临床,这些管线的进展既体现了国产创新的技术突破,也暴露了全球化竞争中的挑战。本文将从靶点赛道、合作模式、临床布局、挑战趋势四个维度,系统...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10